These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
349 related articles for article (PubMed ID: 33183014)
21. Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non-small-cell Lung Cancer. Kawamura T; Kenmotsu H; Omori S; Nakashima K; Wakuda K; Ono A; Naito T; Murakami H; Omae K; Mori K; Tanigawara Y; Nakajima T; Ohde Y; Endo M; Takahashi T Clin Lung Cancer; 2018 Mar; 19(2):e247-e252. PubMed ID: 28866043 [TBL] [Abstract][Full Text] [Related]
22. The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy. Wang Y; Tian P; Xia L; Li L; Han R; Zhu M; Lizaso A; Qin T; Li M; Yu B; Mao X; Han-Zhang H; He Y Lung Cancer; 2020 Aug; 146():165-173. PubMed ID: 32540560 [TBL] [Abstract][Full Text] [Related]
23. Sequential use of EGFR-tyrosine kinase inhibitors based upon EGFR mutation evolution achieves long-term control in a non-small cell lung cancer patient: a case report. Jiang Y; Zhang J; Jiang X; Cheng L; Liao X; Li Y; Zhang M; Chen R; Yin T Ann Palliat Med; 2021 Jun; 10(6):7051-7056. PubMed ID: 33548986 [TBL] [Abstract][Full Text] [Related]
24. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs). Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627 [TBL] [Abstract][Full Text] [Related]
25. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma. Yu G; Xie X; Sun D; Geng J; Fu F; Zhang L; Wang H Int J Clin Exp Pathol; 2015; 8(7):8603-6. PubMed ID: 26339441 [TBL] [Abstract][Full Text] [Related]
26. Co-alteration of EGFR mutation and ALK rearrangement in non-small cell lung cancer: Case series. Shin HJ; Kho BG; Kim MS; Park HY; Kim TO; Kim YI; Lim SC; Park CK; Kim YC; Choi YD; Oh IJ Medicine (Baltimore); 2019 Mar; 98(9):e14699. PubMed ID: 30817606 [TBL] [Abstract][Full Text] [Related]
27. Small cell lung cancer transformation after EGFR-TKIs treatment in lung adenocarcinoma: A case report and literatures review. Chen X; Li D; Miao K; Shou T; Zhang W Medicine (Baltimore); 2023 Jan; 102(4):e32697. PubMed ID: 36705363 [TBL] [Abstract][Full Text] [Related]
28. Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients. Ko R; Kenmotsu H; Serizawa M; Koh Y; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Isaka M; Endo M; Nakajima T; Ohde Y; Yamamoto N; Takahashi K; Takahashi T BMC Cancer; 2016 Nov; 16(1):864. PubMed ID: 27821131 [TBL] [Abstract][Full Text] [Related]
29. Non-Small Cell Lung Cancer with Resistance to EGFR-TKI Therapy: CT Characteristics of T790M Mutation-positive Cancer. Koo HJ; Kim MY; Park S; Lee HN; Kim HJ; Lee JC; Kim SW; Lee DH; Choi CM Radiology; 2018 Oct; 289(1):227-237. PubMed ID: 30015588 [TBL] [Abstract][Full Text] [Related]
30. Transformation of advanced lung adenocarcinoma to acquired T790M resistance mutation adenosquamous carcinoma following tyrosine kinase inhibitor: a case report. Liu Q; Wu L; Zhang S Tumori; 2021 Dec; 107(6):NP5-NP10. PubMed ID: 33896242 [TBL] [Abstract][Full Text] [Related]
31. Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project. Beau-Faller M; Pencreach E; Leduc C; Blons H; Merlio JP; Bringuier PP; de Fraipont F; Escande F; Lemoine A; Ouafik L; Denis M; Hofman P; Lacave R; Melaabi S; Langlais A; Missy P; Morin F; Moro-Sibilot D; Barlesi F; Cadranel J; Lung Cancer; 2020 Feb; 140():19-26. PubMed ID: 31841714 [TBL] [Abstract][Full Text] [Related]
32. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types. Park S; Lee SY; Kim D; Sim YS; Ryu JS; Choi J; Lee SH; Ryu YJ; Lee JH; Chang JH BMC Cancer; 2021 Jan; 21(1):52. PubMed ID: 33430803 [TBL] [Abstract][Full Text] [Related]
33. Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy. Dal Maso A; Lorenzi M; Roca E; Pilotto S; Macerelli M; Polo V; Cecere FL; Del Conte A; Nardo G; Buoro V; Scattolin D; Monteverdi S; Urso L; Zulato E; Frega S; Bonanno L; Indraccolo S; Calabrese F; Conte P; Pasello G Clin Lung Cancer; 2020 Jan; 21(1):1-14.e3. PubMed ID: 31601525 [TBL] [Abstract][Full Text] [Related]
34. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients. Kuiper JL; Heideman DA; Thunnissen E; Paul MA; van Wijk AW; Postmus PE; Smit EF Lung Cancer; 2014 Jul; 85(1):19-24. PubMed ID: 24768581 [TBL] [Abstract][Full Text] [Related]
35. Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib. Zhao Y; Wang S; Zhang B; Qiao R; Xu J; Zhang L; Zhang Y; Han B Target Oncol; 2019 Apr; 14(2):169-178. PubMed ID: 30888598 [TBL] [Abstract][Full Text] [Related]
36. Standardized uptake value on (18)F-FDG-PET/CT is a predictor of EGFR T790M mutation status in patients with acquired resistance to EGFR-TKIs. Yoshida T; Tanaka H; Kuroda H; Shimizu J; Horio Y; Sakao Y; Inaba Y; Iwata H; Hida T; Yatabe Y Lung Cancer; 2016 Oct; 100():14-19. PubMed ID: 27597275 [TBL] [Abstract][Full Text] [Related]
37. Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations. Lou NN; Zhang XC; Chen HJ; Zhou Q; Yan LX; Xie Z; Su J; Chen ZH; Tu HY; Yan HH; Wang Z; Xu CR; Jiang BY; Wang BC; Bai XY; Zhong WZ; Wu YL; Yang JJ Oncotarget; 2016 Oct; 7(40):65185-65195. PubMed ID: 27533086 [TBL] [Abstract][Full Text] [Related]
38. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era? Ou SH; Soo RA Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839 [TBL] [Abstract][Full Text] [Related]